Sign In
The CEO Views Small logos
  • Home
  • Technology
    Artificial Intelligence
    Big Data
    Block Chain
    BYOD
    Cloud
    Cyber Security
    Data Center
    Digital Transformation
    Enterprise Mobility
    Enterprise Software
    IOT
    IT Services
    Innovation
  • Platforms
    How IBM Maximo Is Revolutionizing Asset Management
    How IBM Maximo Is Revolutionizing Asset Management
    IBM
    7 Min Read
    Optimizing Resources: Oracle DBA Support Services for Efficient Database Management
    Oracle
    Oracle
    9 Min Read
    The New Google Algorithm Update for 2021
    google algorithm update 2021
    Google
    5 Min Read
    Oracle Cloud Platform Now Validated for India Stack
    Service Partner Horizontal
    Oracle
    3 Min Read
    Oracle and AT&T Enter into Strategic Agreement
    oracle
    Oracle
    3 Min Read
    Check out more:
    • Google
    • HP
    • IBM
    • Oracle
  • Industry
    Banking & Insurance
    Biotech
    Construction
    Education
    Financial Services
    Healthcare
    Manufacturing
    Mining
    Public Sector
    Retail
    Telecom
    Utilities
    Gaming
    Legal
  • Functions
    RISMA Systems: A Comprehensive Approach to Governance, Risk and Compliance
    Risma Systems
    ENTREPRENEUR VIEWSGDPR
    9 Min Read
    Happiest Minds: A “Privacy by Design” approach is key to creating GDPR compliant businesses
    Happiest Minds 1
    GDPR
    8 Min Read
    Gemserv: GDPR 2020 and Beyond
    Gemserv 1
    GDPR
    9 Min Read
    ECCENCA:GDPR IS STILL AN UNTAMED ANIMAL
    eccenca 1
    GDPR
    6 Min Read
    Boldon James: HOW ENTERPRISES CAN MITIGATE THE GROWING THREATS OF DATA
    Boldon James 1
    GDPR
    8 Min Read
    Check out more:
    • GDPR
  • Magazines
  • Entrepreneurs Views
  • Editor’s Bucket
  • Press Release
  • Micro Blog
  • Events
Reading: PROLUNG: Early Cancer Detection has Better Outcomes and Lower Treatment Costs
Share
The CEO Views
Aa
  • Home
  • Magazines
  • Enterpreneurs Views
  • Editor’s Bucket
  • Press Release
  • Micro Blog
Search
  • World’s Best Magazines
  • Technology
    • Artificial Intelligence
    • Big Data
    • Block Chain
    • BYOD
    • Cloud
    • Cyber Security
    • Data Center
    • Digital Transformation
    • Enterprise Mobility
    • Enterprise Software
    • IOT
    • IT Services
  • Platforms
    • Google
    • HP
    • IBM
    • Oracle
  • Industry
    • Banking & Insurance
    • Biotech
    • Construction
    • Education
    • Financial Services
    • Healthcare
    • Manufacturing
    • Mining
    • Public Sector
    • Retail
    • Telecom
    • Utilities
  • Functions
    • GDPR
  • Magazines
  • Editor’s Bucket
  • Press Release
  • Micro Blog
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
The CEO Views > Blog > Magazine > ENTREPRENEUR VIEWS > PROLUNG: Early Cancer Detection has Better Outcomes and Lower Treatment Costs
ENTREPRENEUR VIEWS

PROLUNG: Early Cancer Detection has Better Outcomes and Lower Treatment Costs

The CEO Views
Last updated: 2024/02/28 at 2:45 AM
The CEO Views
Share
ProLung
ProLung

Lung cancer is the leading cause of cancer deaths worldwide, killing more than colorectal, breast and prostate cancers combined. There is a severe unmet clinical need to reduce the time required to determine malignancy in patients with Indeterminate Pulmonary Nodules (IPN). Patients with IPNs can wait months, or even years, receiving multiple CT scans to confirm malignancy in the lungs. This wait often proves fatal as the cancer advances and spreads. To address this situation, ProLung utilizes a patented non-invasive scanning technique called Electrical Impedance Analytics (EIA) combined with a proprietary algorithm. ProLung is focused on developing, testing and commercializing predictive cancer analytics utilizing bioconductance and Artificial Intelligence (AI) which is designed to accelerate the time to diagnose, expand the therapeutic window for cancer patients and reduce the cost burden to healthcare systems.

THE PROLUNG SYSTEM HAS BEEN DESIGNATED A ‘BREAKTHROUGH DEVICE’ BY THE U.S. FDA

The ProLung System is based on the principles of bioconductance where it measures the electrical impedance of the body. Moreover, the company is building upon earlier published research in this field that demonstrated an electrical impedance difference between malignant and benign breast, thyroid and cervical tissue. The Company continues to expand its intellectual property portfolio.

“Lung cancer patients are often diagnosed too late when the disease is in its later stages and when the five-year survival rate is just 17 percent,” says Jared Bauer, CEO, ProLung. Thus, the company is aiming to help physicians shift the diagnosis to the earliest and most treatable stages, to increase the five-year survival rate to nearly 80 percent. Early cancer detection models have repeatedly shown that outcomes are better and treatment costs are lower for earlier-stage cancers than for advanced-stage cancers. Keeping this in mind, the ProLung Test™, ProLung’s first predictive analytics platform for lung cancer, was developed to contribute to significant survivorship increases and treatment cost advantages.

The FDA designated the ProLung Test as a Breakthrough Device in February 2020.

Through this program, the FDA will provide ProLung with expedited reviews and the Centers for Medicare Medicaid Services (CMS) will provide a simpler and faster pathway to reimbursement. The FDA’s Breakthrough Device program is intended to expedite the development and prioritize the review of certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. Furthermore, this program is intended to help patients have more timely access to these medical devices by expediting their development, assessment, and review while preserving the statutory standards for premarket approval.

As a patient is scanned with the ProLung Test, a tremendous amount of patient-specific data is collected by the company’s system and ProLung believes that AI may help identify previously unrecognized patterns, yielding even greater performance. “The recent advances in AI may provide new avenues to further improve the performance of the ProLung Test,” adds Mr. Bauer.

ProLung is pursuing two development paths concurrently: First, it is focused on gaining FDA clearance to market in order to commercialize its ProLung Test in the USA. Second, the company is also pursuing feasibility research to determine the applicability of its novel EIA system to other cancers. ProLung has already partnered with a hospital to scan breast cancer patients for feasibility research. The company plans to start additional feasibility studies for other cancers shortly.

The CEO Views April 21, 2020
Share this Article
Facebook Twitter LinkedIn Email Copy Link
Previous Article PRO Unlimited PRO UNLIMITED: Helping You Navigate the Complex Contingent Workforce Management Industry
Next Article PumaPay PUMAPAY: The Cryptocurrency Payment Solution for Better Digital Transactions
How to Write a Business Plan in 2023 Comprehensive Guide 1

How to Write a Business Plan in 2023: Comprehensive Guide

February 12, 2024
Avo Solutions Cover
ENTREPRENEUR VIEWS

AVO SOLUTIONS Delivering Value in Chaos

The CEO Views By The CEO Views February 26, 2024
Advance Commerce
ENTREPRENEUR VIEWS

ADVANCED COMMERCE : Online Merchandising Redefined

The CEO Views By The CEO Views February 23, 2024
Leobit
ENTREPRENEUR VIEWS

LEOBIT: Reliable Expert in Web & Mobile Application Development

The CEO Views By The CEO Views February 26, 2024
The Road to Recovery
Micro Blog

The Road to Recovery: What Most Riders Don’t Know After a Motorcycle Crash

The CEO Views By The CEO Views March 28, 2025

How to Do Online Casino Marketing

May 30, 2025

From Boardroom to Marketplace: How CEOs Are Driving Amazon Success

May 30, 2025

A Look at South Florida’s Top Personal Injury Law Firm, Hollander Law Firm Accident Injury Lawyers

May 30, 2025

The Digital Revolution Is Here – And Legacy Payment Systems Are Struggling To Keep Up

May 29, 2025

You Might Also Like

Mike Akard
ENTREPRENEUR VIEWS

A Legacy of Innovation and Excellence

14 Min Read
Nathan Udy, President & CEO
ENTREPRENEUR VIEWS

Nathan Udy: A Visionary Leader Rebuilding the Benefits System

8 Min Read
Jason Lau, CEO
ENTREPRENEUR VIEWS

Jason Lau: Leading with Problem-solving, Adaptability, and Commitment to Long-term Success

8 Min Read
Dr.Che Jordan, CEO
ENTREPRENEUR VIEWS

Dr.Che Jordan: Leading with Compassion to Transform Lives

7 Min Read
Small logos Small logos

© 2025 All rights reserved. The CEO Views

  • About Us
  • Privacy Policy
  • Advertise with us
  • Reprints and Permissions
  • Business Magazines
  • Contact
Reading: PROLUNG: Early Cancer Detection has Better Outcomes and Lower Treatment Costs
Share

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?